Trust Signals
- No affiliate relationships with any compounding pharmacy or tirzepatide supplier.
- Every storage claim is sourced to a named document. Where manufacturer data does not exist for compounded forms, USP standards are cited and labeled as such.
-
FDA-approved Mounjaro and Zepbound single-dose pens are stable refrigerated (2 to 8 degrees C) until the printed expiry, or at room temperature up to 21 days once removed. Compounded multi-dose vials typically carry a 28-day beyond-use date after first puncture, or up to 90 days unopened, per USP 797 and individual pharmacy dating.
See your personalized options in about 2 minutes. Free and private. See my options →
What happens to tirzepatide if the fridge gets too warm?
Temperatures above 30 degrees C accelerate peptide bond hydrolysis and aggregation. The FDA-approved pen label allows up to 30 degrees C for 21 days; beyond that the product should be discarded. Brief excursions to 25 degrees C for under a few hours are generally considered low risk based on manufacturer excursion data, but compounded vials have less published excursion tolerance.Can tirzepatide be frozen?
No. Freezing causes ice crystal formation that disrupts the peptide's tertiary structure and can cause aggregation. Eli Lilly explicitly states Mounjaro and Zepbound must not be frozen. Discard any vial or pen that has been frozen.Does a compounded tirzepatide vial last longer than the brand-name pen?
Unopened, a compounded vial may carry a similar nominal expiry to an approved pen. Once punctured, the multi-dose vial is typically limited to 28 days by USP 797 beyond-use dating, which is more conservative than the brand pen's single-dose format. The pen has no puncture-related contamination risk.How can I tell if refrigerated tirzepatide has gone bad?
Discard if you see visible particles, cloudiness, or discoloration. Tirzepatide solution should be clear to slightly yellow and particle-free. A color shift toward brown or orange suggests oxidative degradation. Note that subtle chemical degradation can occur before any visual change, so date-tracking matters even if the solution looks clear.What is the room-temperature stability of tirzepatide?
Eli Lilly's label states Mounjaro and Zepbound pens may be kept at room temperature (up to 30 degrees C or 86 degrees F) for a maximum of 21 days, after which they must be discarded even if not fully used. Compounded vials generally follow USP guidance; specific room-temperature BUDs vary by pharmacy and formulation.Why does tirzepatide need refrigeration at all?
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist. At elevated temperatures, peptide bonds hydrolyze, disulfide-adjacent residues oxidize, and the fatty-acid chain attached at lysine 26 can facilitate aggregation. Cold temperatures slow all three processes by reducing molecular kinetic energy and water activity at the peptide surface.Does tirzepatide degrade faster once the vial is punctured?
Yes. Each needle puncture introduces a small risk of microbial contamination and allows oxygen ingress through the stopper. USP 797 therefore assigns a 28-day beyond-use date for multi-dose compounded sterile preparations under most conditions, which is why compounded vials carry a shorter post-puncture window.What should I look for on a compounded tirzepatide COA?
Look for identity confirmation by HPLC or mass spectrometry, purity greater than 98 percent, endotoxin testing (LAL method, limit less than 5 EU/kg/hr for injectable peptides), sterility test result, pH (typically 6.0 to 7.5 for peptide injectables), and the beyond-use date with storage condition. A COA lacking mass spec identity or endotoxin data is incomplete.Can tirzepatide be stored in an insulin-style travel cooler?
Yes, provided the cooler maintains 2 to 8 degrees C and does not allow freezing contact with ice packs. Gel-pack coolers designed for insulin typically work well. Avoid direct contact between the vial or pen and a frozen gel pack; a paper or foam barrier prevents freeze damage to the outer surface and accidental local freezing.Does tirzepatide lose potency gradually or all at once?
Potency loss is gradual and follows degradation kinetics, not a cliff. The drug remains largely active within labeled storage windows. Beyond those windows, degradation products accumulate progressively; some are inactive fragments and some may be mildly immunogenic. There is no reliable visual or at-home chemical test to quantify potency loss.How does tirzepatide fridge stability compare to semaglutide?
FDA-approved semaglutide (Ozempic, Wegovy) shares a similar refrigerated storage requirement of 2 to 8 degrees C and allows 56 days at room temperature after first use for Ozempic pens, versus 21 days for tirzepatide pens. Both must not be frozen. Semaglutide's slightly longer room-temperature window reflects formulation differences, not greater inherent peptide stability.Sources
- Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. Revised 2024. Available at: accessdata.fda.gov.
- Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. Revised 2024. Available at: accessdata.fda.gov.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. SURMOUNT-1 trial.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. STEP 1 trial.
- United States Pharmacopeia. USP 797: Pharmaceutical Compounding - Sterile Preparations. 2023 revision. USP-NF.
- United States Pharmacopeia. USP 85: Bacterial Endotoxins Test. Current edition. USP-NF.
- United States Pharmacopeia. USP 71: Sterility Tests. Current edition. USP-NF.
- International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.
- Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Revised 2024. Available at: accessdata.fda.gov.
- FDA. Compounded Drug Products That Are Essentially a Copy of a Commercially Available Drug Product Under Section 503B. Guidance for Industry. 2018.
- Hawe A, Wiggenhorn M, van de Weert M, Garber JJ, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. Journal of Pharmaceutical Sciences. 2012;101(3):895-913.
Footer Disclaimers
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →